There is strong evidence that percutaneous coronary interventions (PCI) reduce the risk of myocardial infarction and death among patients with acute coronary syndromes. However, these benefits have not been established for patients with stable coronary artery disease. For such patients, PCI relieves angina and improves quality of life, but studies have found no evidence that the procedure reduces mortality or risk of myocardial infarction compared with the best medical treatment.
1 Emphasis on the limited role of PCI for patients with stable disease may have contributed to a decrease in its use in recent years.
In a linked paper (doi:10.1136/bmj.g3859) Windecker and colleagues 2 report the results of a meta-analysis to compare the outcomes of patients with stable disease who were assigned to initial medical treatment or to medical treatment plus coronary artery revascularisation. Importantly, given the evolution of percutaneous devices and as a result changing comparator treatments (see fig 1 in the linked paper), a network based analysis was needed to identify potential sequential changes over time. The analysis incorporated data from over 93 000 patients randomised in 100 trials and collectively followed for more than 260 000 patient years. The primary endpoint was all cause mortality.
The authors' findings corroborate consistent observations from individual trials of coronary artery bypass grafting (CABG); surgical revascularisation significantly reduced mortality compared with medical treatment (20% relative reduction), with a narrow credibility interval. In contrast and despite generally including a larger number of patients, trials, and patient years of follow-up, revascularisation with balloon angioplasty, bare metal stents, and first generation drug eluting stents did not. These earlier devices collectively averaged an impact on mortality (non-significant 10% relative reduction) about half that provided by CABG.
Lastly, in 21 trials with over 27 000 patient years of follow-up, the newest PCI devices, so called second generation drug eluting stents, reduced mortality by a significant 25-35% compared with best medical treatment. Their effect on mortality seems comparable to that of CABG, although with wider credibility intervals. These results suggest that the latest evolution of PCI has crossed that elusive threshold-compared with medical treatment alone, all cause mortality was significantly reduced among patients with stable coronary artery disease undergoing PCI with second generation drug eluting stents. This is an important milestone for interventional cardiology and represents the culmination of decades of iterative scientific advances refining techniques, devices, and drug treatments. Bare metal stents practically eliminated abrupt vessel closure. Advanced intracoronary imaging helped refine stenting techniques, and the use of oral dual antiplatelet therapy reduced the risk of stent thrombosis to under 1%. 3 First generation drug eluting stents reduced the risk of restenosis and need for repeat revascularisation by more than 50% compared with bare metal stents. 4 5 Most recently, innovations in stent design, polymer properties, and drug elution kinetics led to a second generation of drug eluting stents with enhanced efficacy, and these further reduced the risk of repeat revascularisation, subsequent myocardial infarction, 6 and stent thrombosis. 7 How might revascularisation help prevent myocardial infarction or even death in patients with stable but severe atherosclerotic heart disease? Unquestionably, severe myocardial ischaemia can reduce the threshold for fatal ventricular arrhythmias and in the long term impair left ventricular function. For patients with stable ischaemic heart disease these risks are low but cumulative over time and proportional to the extent of vulnerable myocardium. Revascularisation decreases or eliminates myocardial ischaemia, yet it is intuitive that for a revascularisation strategy to reduce mortality in a stable cohort it must be extremely effective, durable, and have a low complication rate.
For years, CABG has been known to reduce mortality if the ischaemic burden was large. Early PCI procedures were effective in reducing ischaemia, but the revascularisation provided by CABG was more extensive (for example, bypassing total vessel occlusions) and more durable (associated with lower rates of subsequent PCI or CABG).
With serial advances in percutaneous devices and concomitant drug treatments, the durability of percutaneous revascularisation has sequentially improved. Bare metal stents have proved better Studies included in this network meta-analysis spanned several decades, during which time advances in optimal medical treatment also improved outcomes for patients with coronary artery disease. Survival was improved by routine treatment with statins, as well as with β blockers and angiotensin converting enzyme inhibitors for those with ventricular dysfunction. Revascularisation was not and should not be considered an alternative to these evidence based medical treatments but rather used as an additional strategy to minimise myocardial ischaemia. Indeed, the many advances in medical treatment should be credited for helping the focal treatment approach of drug eluting stents to approximate the results of CABG.
Windecker and colleagues' findings should reassure both doctors and patients that, when indicated, referring patients with stable coronary artery disease for PCI or CABG is reasonable and beneficial. However, the lack of patient level data does not help doctors identify subgroups of patients who are likely to benefit most from a drug eluting stent, CABG, or medical treatment alone.
For answers to these questions we must turn to dedicated randomised trials evaluating the options in specific clinical settings and patient subgroups. 8 9 Therapeutic choices must also take full account of individual patient characteristics that can influence outcome after the various treatment options. 10 Competing interests: We have read and understood the BMJ Group policy on declaration of interests and declare the following interests: none.
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